SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan. 2, 2019--
Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the
37th Annual J. P. Morgan Healthcare Conference on Wednesday,
January 9, 2019 at 11:30 am PT / 2:30 pm ET. Gerrit Klaerner, Ph.D.,
Tricida’s chief executive officer and president, will provide a company
overview, business update and progress on the company’s key initiatives.
A live webcast of the presentation will be accessible on the Tricida
website at IR.Tricida.com.
An archive of the webcast will be available for 90 days following the
Tricida, Inc. is a pharmaceutical company focused on the development and
commercialization of TRC101, a non-absorbed, orally-administered polymer
designed as a potential treatment for metabolic acidosis in patients
with chronic kidney disease (CKD). Metabolic acidosis is a condition
commonly caused by CKD that is believed to accelerate the progression of
kidney deterioration. Tricida has successfully completed a pivotal Phase
3, double-blind, placebo-controlled trial of TRC101 in patients with CKD
and metabolic acidosis. For more information about Tricida, please visit
the company’s website at www.Tricida.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190102005417/en/
Source: Tricida, Inc.
Jackie Cossmon, IRC
Vice President of Investor
Relations and Communications